Capital International’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$64.6M Sell
70,183
-3,054
-4% -$3.1M 2.39% 7
2025
Q4
$78.7M Buy
73,237
+4,497
+7% +$4.3M 2.77% 6
2025
Q3
$52.4M Sell
68,740
-2,978
-4% -$2.22M 1.9% 10
2025
Q2
$55.9M Sell
71,718
-657
-0.9% -$511K 2.14% 8
2025
Q1
$59.8M Buy
72,375
+3,645
+5% +$3.03M 2.61% 7
2024
Q4
$53.1M Buy
68,730
+2,015
+3% +$1.67M 2.16% 8
2024
Q3
$59.1M Sell
66,715
-1,223
-2% -$1.1M 2.55% 6
2024
Q2
$61.5M Sell
67,938
-4,525
-6% -$3.62M 2.84% 5
2024
Q1
$56.4M Sell
72,463
-27,522
-28% -$19.6M 2.7% 4
2023
Q4
$58.3M Sell
99,985
-2,100
-2% -$1.23M 2.99% 5
2023
Q3
$54.8M Sell
102,085
-26
-0% -$13.4K 3.15% 5
2023
Q2
$47.9M Sell
102,111
-4,304
-4% -$1.8M 2.68% 5
2023
Q1
$36.5M Buy
106,415
+376
+0.4% +$127K 2.19% 5
2022
Q4
$38.8M Buy
106,039
+818
+0.8% +$290K 2.67% 3
2022
Q3
$34M Buy
105,221
+5,159
+5% +$1.63M 2.37% 5
2022
Q2
$32.4M Buy
100,062
+50,586
+102% +$15.2M 2.44% 6
2022
Q1
$14.2M Buy
49,476
+15,084
+44% +$3.88M 0.81% 31
2021
Q4
$9.5M Buy
34,392
+6,355
+23% +$1.61M 0.48% 63
2021
Q3
$6.48M Sell
28,037
-324
-1% -$80K 0.35% 79
2021
Q2
$6.51M Buy
28,361
+61
+0.2% +$12.3K 0.36% 74
2021
Q1
$5.29M Buy
+28,300
New +$5.54M 0.32% 92
2020
Q4
Sell
-9,025
Closed -$1.34M 162
2020
Q3
$1.34M Buy
9,025
+149
+2% +$23.1K 0.09% 136
2020
Q2
$1.46M Sell
8,876
-12,517
-59% -$1.92M 0.14% 118
2020
Q1
$2.97M Sell
21,393
-7,024
-25% -$965K 0.33% 76
2019
Q4
$3.73M Sell
28,417
-15,866
-36% -$1.84M 0.39% 70
2019
Q3
$4.95M Buy
44,283
+3,307
+8% +$368K 0.75% 38
2019
Q2
$4.54M Sell
40,976
-2,574
-6% -$303K 1.08% 25
2019
Q1
$5.65M Buy
43,550
+900
+2% +$109K 1.35% 18
2018
Q4
$4.93M Buy
42,650
+27,000
+173% +$3.02M 1.34% 19
2018
Q3
$1.68M Sell
15,650
-8,765
-36% -$876K 0.52% 56
2018
Q2
$2.08M Sell
24,415
-300
-1% -$24.6K 0.36% 81
2018
Q1
$1.91M Buy
24,715
+1,323
+6% +$107K 0.34% 85
2017
Q4
$1.98M Sell
23,392
-9,365
-29% -$797K 0.37% 80
2017
Q3
$2.8M Hold
32,757
0.18% 84
2017
Q2
$2.7M Sell
32,757
-800
-2% -$65.3K 0.18% 86
2017
Q1
$2.82M Sell
33,557
-13,400
-29% -$1.07M 0.18% 86
2016
Q4
$3.45M Sell
46,957
-122,543
-72% -$9.13M 0.24% 84
2016
Q3
$13.6M Sell
169,500
-50,400
-23% -$4.03M 0.96% 40
2016
Q2
$17.3M Sell
219,900
-109,800
-33% -$8.27M 1.25% 31
2016
Q1
$23.7M Buy
329,700
+200
+0.1% +$15.1K 1.53% 19
2015
Q4
$27.8M Sell
329,500
-23,300
-7% -$1.93M 1.75% 14
2015
Q3
$29.5M Buy
352,800
+75,400
+27% +$6.37M 1.96% 12
2015
Q2
$23.2M Buy
+277,400
New +$21.1M 1.37% 24

Other funds holding LLY

Capital International's LLY Position: Q1 2026 in Review

Capital International reduced its Eli Lilly (LLY) stake by 4.2% in Q1 2026, selling an estimated $3.1M and leaving 70,183 shares worth $64.6M. The position accounts for 2.39% of the portfolio, ranked #7.

Capital International first reported a position in LLY in Q2 2015 and has held it in 43 quarters since. The position peaked at $78.7M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capital International held 70,183 shares of Eli Lilly worth $64.6M as of Q1 2026.
  • Capital International sold 3,054 Eli Lilly shares in Q1 2026, an estimated $3.1M.
  • Eli Lilly made up 2.39% of Capital International's portfolio in Q1 2026, its #7 holding.
  • Capital International first reported a position in Eli Lilly in Q2 2015 and has held it in 43 quarters since.
  • Capital International's Eli Lilly position peaked at $78.7M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital International's 13F filing for Q1 2026, filed 13 May 2026.